Get the app
US › Healthcare

Oculis Holding AG Ordinary shares (OCS)

US · Healthcare · Biotechnology

$7.29-1.49%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-10.0M
EPS
$-0.20
EPS estimate
$-0.48

EPS came in at -0.20 against a street estimate of -0.48 — a beat of 58.3%.

Key statistics

Market cap
$485.3M
Forward P/E
0.0
P/B
2.07
Book value
$4.24
EPS (TTM)
$-1.74
52-week high
$34.48
52-week low
$7.32
50-day MA
$11.14
200-day MA
$19.77
Beta
0.27

Analyst view

Analysts rate Oculis Holding AG Ordinary shares a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $36.58.

Shareholding

Insiders
3.53%
Institutions
47.53%

Largest institutional holders

FundStake
EQT Fund Management S.à r.l.11.29%
Gildi - lifeyrissjodur3.95%
Aberdeen Group PLC3.51%
Millennium Management LLC3.32%
Pivotal bioVenture Partners Investment Advisor LLC2.45%
Citadel Advisors Llc1.60%
BRAIDWELL LP1.35%
Perceptive Advisors LLC1.31%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Oculis Holding AG Ordinary shares — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.